Trial Profile

A Phase I trial of DD-S052P for the treatment of Sepsis and Gram negative infections

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DD S052P (Primary)
Indications Gram-negative infections; Sepsis
Focus Adverse reactions
Sponsors HLB

Most Recent Events

12 Feb 2026 New trial record
13 Jan 2026 According to HLB media release, In July, HLB Science received approval from the French Ministry of Food and Drug Safety (ANSM) for a phase 1 clinical trial plan (IND) for DD-S052P to develop new drugs for sepsis and gram-negative superbacterial infections. Clinical trials will be conducted at Eurofiins Optimed in France.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com